Eyetech Pharmaceuticals
New York
About Eyetech Pharmaceuticals
Eyetech Pharmaceuticals is a biopharmaceutical company that specializes in novel therapeutics to treat diseases of the eye. The company conducted research and development into wet age-related macular degeneration diseases, which was seen as a breakthrough in the field. Valeant Pharmaceuticals International acquired Eyetech for US$22 million in 2012.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Delisted
- Employees: 251 – 500
- Total funding: $108.5M
- Funding stage: M&A
- Last round: Series C (Aug 2001)
- Ticker: nasdaq:EYET
- Website: eyetk.com
Industries & Categories
Biopharma, Biotechnology, Medical
Canonical: https://fsome.com/organization/eyetech-pharmaceuticals-3366449 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.